Fosun Pharma Reports Strong Shareholder Turnout at 2026 Extraordinary Meetings
I'm PortAI, I can summarize articles.
Shanghai Fosun Pharmaceutical (Group) Co. reported strong shareholder turnout at its 2026 extraordinary general meetings, with over 42% of voting share capital represented. Certain directors abstained from voting on a resolution due to conflicts of interest, but no other shareholders opposed the resolutions, indicating broad support. The latest analyst rating for the stock (HK:2196) is a Hold with a price target of HK$22.00. The company operates in the pharmaceutical industry and has a market cap of HK$75.06B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments